Praxis Precision Medicines, Inc. (PRAX) — Financial statements
Income statement, balance sheet, and cash flow for Praxis Precision Medicines, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00↓100.0% | 9↑249.5% | 2 | 0.00 | 0.00 | |
| Cost of Revenue | 0.14↓99.9% | 152↑75.7% | 87↓43.8% | 154 | 0.00 | |
| Gross Profit | -0.14↑99.9% | -144↓70.6% | -84↑45.4% | -154 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 267↑75.3% | 152↑75.7% | 87↓44.0% | 155↑28.9% | 120 | |
| General & Administrative Expenses | 59↑4.9% | 56↑33.9% | 42↓29.4% | 60↑26.5% | 47 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 59↑4.9% | 56↑33.9% | 42↓29.4% | 60↑26.5% | 47 | |
| Other Expenses | 0.00↑100.0% | -152↓75.7% | -87↑43.7% | -154 | 0.00 | |
| Operating Expenses | 326↑479.1% | 56↑33.9% | 42↓30.5% | 61↓63.8% | 167 | |
| Total Costs & Expenses | 326↑56.3% | 209↑62.0% | 129↓40.1% | 215↑28.5% | 167 | |
| Operating Results | ||||||
| Operating Income | -326↓63.0% | -200↓58.4% | -126↑41.2% | -215↓28.5% | -167 | |
| Depreciation & Amortization | 0.14↓60.9% | 0.36↓17.1% | 0.43↑3.1% | 0.42↑130.2% | 0.18 | |
| EBITDA | -303↓51.7% | -200↓58.7% | -126↑41.0% | -214↓27.8% | -167 | |
| EBIT | -303↓51.5% | -200↓58.4% | -126↑40.9% | -214↓27.9% | -167 | |
| Interest & Other Income | ||||||
| Net Interest Income | 23↑32.2% | 17 | 0.00 | 0.00 | 0.00 | |
| Interest Income | 23↑32.2% | 17 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | -23 | 0.00 | 0.00↑100.0% | -1 | 0.00 | |
| Other Income / Expenses | 23↑32.2% | 17↑460.3% | 3↑223.5% | 0.96↑253.1% | 0.27 | |
| Income Before Tax | -303↓65.9% | -183↓48.3% | -123↑42.4% | -214↓28.1% | -167 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -303↓65.9% | -183↓48.3% | -123↑42.4% | -214↓28.1% | -167 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -303↓65.9% | -183↓48.3% | -123↑42.4% | -214↓28.1% | -167 | |
| Bottom-Line Net Income | -303↓65.9% | -183↓48.3% | -123↑42.4% | -214↓28.1% | -167 | |
| EPS (Basic) | -13.48↓32.0% | -10.21↑45.4% | -18.69↑73.0% | -69.33↓17.6% | -58.96 | |
| EPS (Diluted) | -13.48↓32.0% | -10.21↑45.4% | -18.69↑73.0% | -69.33↓17.6% | -58.96 | |
| Weighted Average Shares | 23↑25.7% | 18↑171.5% | 7↑114.6% | 3↑8.6% | 3 | |
| Weighted Average Diluted Shares | 23↑25.7% | 18↑171.5% | 7↑114.6% | 3↑8.6% | 3 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.